419 related articles for article (PubMed ID: 22179316)
1. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway.
Jeong H; Cohen DE; Cui L; Supinski A; Savas JN; Mazzulli JR; Yates JR; Bordone L; Guarente L; Krainc D
Nat Med; 2011 Dec; 18(1):159-65. PubMed ID: 22179316
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.
Jiang M; Wang J; Fu J; Du L; Jeong H; West T; Xiang L; Peng Q; Hou Z; Cai H; Seredenina T; Arbez N; Zhu S; Sommers K; Qian J; Zhang J; Mori S; Yang XW; Tamashiro KL; Aja S; Moran TH; Luthi-Carter R; Martin B; Maudsley S; Mattson MP; Cichewicz RH; Ross CA; Holtzman DM; Krainc D; Duan W
Nat Med; 2011 Dec; 18(1):153-8. PubMed ID: 22179319
[TBL] [Abstract][Full Text] [Related]
3. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.
Chaturvedi RK; Hennessey T; Johri A; Tiwari SK; Mishra D; Agarwal S; Kim YS; Beal MF
Hum Mol Genet; 2012 Aug; 21(15):3474-88. PubMed ID: 22589249
[TBL] [Abstract][Full Text] [Related]
4. Finding a sirtuin truth in Huntington's disease.
La Spada AR
Nat Med; 2012 Jan; 18(1):24-6. PubMed ID: 22227661
[No Abstract] [Full Text] [Related]
5. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
[TBL] [Abstract][Full Text] [Related]
6. Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.
Martin E; Betuing S; Pagès C; Cambon K; Auregan G; Deglon N; Roze E; Caboche J
Hum Mol Genet; 2011 Jun; 20(12):2422-34. PubMed ID: 21493629
[TBL] [Abstract][Full Text] [Related]
7. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
[TBL] [Abstract][Full Text] [Related]
8. cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues.
Chiang MC; Lee YC; Huang CL; Chern Y
J Biol Chem; 2005 Apr; 280(14):14331-40. PubMed ID: 15689617
[TBL] [Abstract][Full Text] [Related]
9. Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites.
Liot G; Zala D; Pla P; Mottet G; Piel M; Saudou F
J Neurosci; 2013 Apr; 33(15):6298-309. PubMed ID: 23575829
[TBL] [Abstract][Full Text] [Related]
10. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
Dunah AW; Jeong H; Griffin A; Kim YM; Standaert DG; Hersch SM; Mouradian MM; Young AB; Tanese N; Krainc D
Science; 2002 Jun; 296(5576):2238-43. PubMed ID: 11988536
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
12. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.
Gharami K; Xie Y; An JJ; Tonegawa S; Xu B
J Neurochem; 2008 Apr; 105(2):369-79. PubMed ID: 18086127
[TBL] [Abstract][Full Text] [Related]
13. Targeting sirtuin-1 in Huntington's disease: rationale and current status.
Duan W
CNS Drugs; 2013 May; 27(5):345-52. PubMed ID: 23549885
[TBL] [Abstract][Full Text] [Related]
14. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
[TBL] [Abstract][Full Text] [Related]
15. A novel target for Huntington's disease: ERK at the crossroads of signaling. The ERK signaling pathway is implicated in Huntington's disease and its upregulation ameliorates pathology.
Bodai L; Marsh JL
Bioessays; 2012 Feb; 34(2):142-8. PubMed ID: 22334892
[TBL] [Abstract][Full Text] [Related]
16. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease.
Zuccato C; Belyaev N; Conforti P; Ooi L; Tartari M; Papadimou E; MacDonald M; Fossale E; Zeitlin S; Buckley N; Cattaneo E
J Neurosci; 2007 Jun; 27(26):6972-83. PubMed ID: 17596446
[TBL] [Abstract][Full Text] [Related]
17. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.
Bates EA; Victor M; Jones AK; Shi Y; Hart AC
J Neurosci; 2006 Mar; 26(10):2830-8. PubMed ID: 16525063
[TBL] [Abstract][Full Text] [Related]
18. The role of Twist1 in mutant huntingtin-induced transcriptional alterations and neurotoxicity.
Pan Y; Zhu Y; Yang W; Tycksen E; Liu S; Palucki J; Zhu L; Sasaki Y; Sharma MK; Kim AH; Zhang B; Yano H
J Biol Chem; 2018 Jul; 293(30):11850-11866. PubMed ID: 29891550
[TBL] [Abstract][Full Text] [Related]
19. CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity.
Arango M; Holbert S; Zala D; Brouillet E; Pearson J; Régulier E; Thakur AK; Aebischer P; Wetzel R; Déglon N; Néri C
J Neurosci; 2006 Apr; 26(17):4649-59. PubMed ID: 16641246
[TBL] [Abstract][Full Text] [Related]
20. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
Xie Y; Hayden MR; Xu B
J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
